Perrigo Reports In-Line Q2 EPS
- ByInvesting.com-
Perrigo (PRGO) reported Q2 EPS of $0.43, in-line with the analyst estimate of $0.43. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.06...
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Perrigo Company PLC (PRGO)
41.68
-0.19(-0.45%)
- Volume:264,219
- Day's Range:41.48 - 42.02
- 52 wk Range:31.32 - 50.90
PRGO Overview
- Prev. Close
- 41.87
- Day's Range
- 41.48-42.02
- Revenue
- 4.34B
- Open
- 41.82
- 52 wk Range
- 31.32-50.9
- EPS
- -0.872
- Volume
- 264,219
- Market Cap
- 5.6B
- Dividend (Yield)
- 1.04(2.48%)
- Average Vol. (3m)
- 1,373,462
- P/E Ratio
- -63.78
- Beta
- 0.907
- 1-Year Change
- 2.25%
- Shares Outstanding
- 134,551,671
- Next Earnings Date
- Nov 09, 2022
What is your sentiment on Perrigo?
or
Vote to see community's results!
Perrigo Company PLC News
- Target to add Bobbie brand infant formula to stores as shortage persists
- ByReuters-
By Jessica DiNapoli NEW YORK (Reuters) -Target Corp has begun carrying Bobbie brand infant formula in some stores this week and the vast majority of its locations will be selling...
- Perrigo's HRA Pharma Submits FDA Application for First OTC Birth Control Pill
- ByInvesting.com-
By Sam BougheddaConsumer self-care products firm Perrigo Company (NYSE:PRGO) announced Monday that its subsidiary, HRA Pharma, has submitted an application to the United States...
Perrigo Company PLC Analysis
- Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund...
- 3 Stocks To Watch In The Coming Week: GameStop, Match Group, Kroger
Equity investors will likely seek direction after Friday's disappointing August jobs report amid surging COVID-19 cases in the US, adding another layer of uncertainty to the...
- Perrigo (PRGO) Q2 Earnings and Revenues Lag Estimates
Perrigo (PRGO) came out with quarterly earnings of $0.50 per share, missing the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $1.03 per share a year...
Perrigo Company PLC Company Profile
Perrigo Company PLC Company Profile
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that enables consumers to prevent or treat conditions that can be self-managed. The Company operates through two segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the United States (U.S) and Canada. CSCA segment products sold under brands, such as Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees. The CSCI segment comprises consumer self-care business primarily branded in Europe and Australia, store brand business in the United Kingdom and parts of Europe and Asia. The CSCI segment primarily focuses on building local and regional brands sold through merchandisers, drug stores, pharmacies, and e-commerce channels.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Neutral | Sell |
| Technical Indicators | Buy | Strong Sell | Buy | Buy | Sell |
| Summary | Buy | Sell | Neutral | Neutral | Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 8.14 | 8.15 | 7.85 | -0.22 | -2.62% | 3.61M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 31.85 | 31.88 | 30.71 | -0.90 | -2.75% | 4.48M | NYSE | |||
| 1.165 | 1.19 | 1.15 | -0.0450 | -3.72% | 1.71M | NYSE | |||
| 1.09 | 1.09 | 1.05 | -0.0100 | -0.91% | 81.22K | NYSE | |||
| 45.46 | 45.49 | 44.78 | -0.80 | -1.73% | 1.17M | NYSE | |||
| 3.54 | 3.55 | 3.47 | -0.060 | -1.67% | 7.83M | NYSE | |||
| 20.39 | 20.52 | 19.80 | +0.27 | +1.34% | 702.16K | NASDAQ | |||
| 7.44 | 7.54 | 6.73 | +0.570 | +8.30% | 4.41M | NYSE | |||
| 14.33 | 15.06 | 13.37 | +1.38 | +10.67% | 77.59M | NASDAQ | |||
| 49.77 | 49.85 | 47.44 | -1.12 | -2.19% | 1.49M | NYSE | |||
| 15.24 | 15.30 | 15.00 | +0.03 | +0.16% | 1.60M | OTC Markets | |||
| 0.78 | 0.79 | 0.776 | -0.010 | -1.27% | 5.42K | NASDAQ | |||
| 0.0006 | 0.0006 | 0.0006 | 0.00000 | 0.00% | 0.00 | OTC Markets | |||
| 42.83 | 42.85 | 42.42 | -0.68 | -1.56% | 1.82M | NYSE |
- Dec 06, 2021, 18:34This should be a moderate BUY
- Aug 11, 2021, 21:0142.5. buy
- Aug 11, 2021, 20:14sell
- Jun 05, 2021, 20:27md ayas
- Feb 28, 2019, 16:19February 27 Earnings call was terribly executed. The CEO was full of excuses as to why he is clueless on the future of the company. They missed earnings and could not give clear answers as the reasons. They demanded for their investors to wait until May 6 for guidance, as they do not know what they are going to do with the business. They only thing they would say is the product pricing is a headwind that will not end, they want to divest the Rx business but there are no buyers, and that they will continue to fight the tax dispute but can not make any claims about its possible outcome.
- Mar 11, 2020, 07:01he is just doing that he was joking around
- Jul 31, 2017, 11:49I'll be glad if it goes up to $85. Let's hope it will exceed analysts' expectations and maybe beat by a few cents. Cross your fingers pal!
- May 13, 2016, 11:37prgo had good Q1 2016 earning why she isnt at 130$ yet?